By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

This is no reason to panic.

The company overtook early GLP-1 leader Novo Nordisk. Eli Lilly is increasingly reliant on its GLP-1 drugs. Eli Lilly (NYSE: ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through its LillyDirect platform.

Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity ...

Katie Duffy had already lost 50 pounds on Zepbound when she learned some unsettling news: Her drug-benefit plan would no longer cover the medication because of new, more favorable pricing for another ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Zepbound and Wegovy treat weight loss and weight management in adults with obesity or overweight. Both drugs are also approved to treat other conditions. These drugs are given as weekly injections, ...